Market News & Trends
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial
ADC Therapeutics recently announced the first patient has been dosed in a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and anti-tumor activity of…
CytoDyn Files for Orphan Drug Designation for Triple-Negative Breast Cancer
CytoDyn Inc. recently announced it was able to reduce by more than 98% the incidence of human breast cancer metastasis in a mouse xenograft model…
Sapreme Technologies to Develop an Oligonucleotide Delivery Platform
Sapreme Technologies has been awarded a $7.71 million grant together with a multidisciplinary consortium including 11 other academic and industrial parties.
PPD & HLT to Create Data Science-Driven Clinical Research Solutions
Pharmaceutical Product Development, LLC and Happy Life Tech of China have signed an exclusive agreement to develop a distinctive service offering for the China drug development market delivering data science-driven clinical trials and real-world evidence of drug products’ effectiveness, safety, and value.
Moleculin Announces Out-Licensing Deal to Accelerate Preclinical & Clinical Development
Moleculin Biotech, Inc. recently announced it has entered into a sub-license agreement with WPD Pharmaceuticals (WPD), located in Poland.
Avalon GloboCare Announces Breakthrough in Identifying Human Angiogenic Exosomes/Extracellular Vesicles (EV) Derived From Endothelial Cells
Avalon GloboCare Corp. recently announced its ongoing co-development program with Weill Cornell Medicine, led by Yen-Michael Hsu, MD, PhD, Director of cGMP Cellular Therapy Facility…
Eton Pharmaceuticals Enters Into License Agreement for Two Branded Hospital Product Candidates
Eton Pharmaceuticals, Inc. recently announced that it has entered into an exclusive licensing and supply agreement with Sintetica SA, a Swiss-based pharmaceutical company, to obtain…
Aduro Announces First Patient Dosed in Phase 1 Study
Aduro Biotech, Inc. recently announced the first patient has been dosed in a Phase 1 trial of ADU-S100 (MIW815), a novel stimulator of interferon genes…
Genocea Announces Private Placement Financing of Up to $39 Million
Genocea Biosciences, Inc. recently announced it has entered into a private placement with certain existing and new investors providing for the purchase of up to…
Despite Recent Setbacks, the Ophthalmology Market Still Offers Vast Potential
Despite the ophthalmology market experiencing several research and development (R&D) setbacks during 2018, the launch of three new drugs highlights that the market still offers…
Active Biotech's Partner NeoTX Enters Clinical Collaboration With AstraZeneca
Active Biotech recently announced its partner NeoTX entered a clinical collaboration with AstraZeneca Group Plc global biologics research and development arm, MedImmune, to support Phase…
Passage Bio Launches With $115.5 Million Financing to Develop AAV-Delivered Therapeutics
Passage Bio recently debuted with a $115.-million Series A financing led by OrbiMed Advisors and joined by Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital and Lilly Asia Ventures.
DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical
DiaMedica Therapeutics Inc. recently announced it has initiated dosing patients with chronic kidney disease (CKD) in a Phase Ib clinical study evaluating DM199.
Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License: Triggers Milestone
Codexis, Inc. recently announced that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialization of Codexis’ novel, orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU), an orphan metabolic disorder.
Verseon Reports First Dosing in Phase 1 Trial on New Precision Oral Drug
Verseon’s Phase 1 trial in healthy volunteers, which recently started dosing, could lead to a new treatment standard for millions of cardiac patients who would…
ProteoNic Biotechnology Licenses Protein Production Technology to Eli Lilly
ProteoNic Biotechnology BV recently announced that it licensed its 2G UNic technology for boosting recombinant protein production to Eli Lilly and Company. Under the agreement,…
HiberCell Launches to Prevent Cancer Relapse & Metastasis With Novel Therapeutics
HiberCell recently launched with $60.75 million in Series A funding led by ARCH Venture Partners. HiberCell is the first company exclusively focused on tumor dormancy…
Evotec & Galapagos Enter Global Collaboration
Evotec AG and Galapagos NV recently announced a global collaboration focused on a novel target for fibrosis and other indications. The collaboration concerns a small…
argenx & Halozyme Enter Global Collaboration & License Agreement
argenx and Halozyme Therapeutics, Inc. recently announced a global collaboration and license agreement that enables use by argenx of Halozyme’s ENHANZE drug delivery technology to…
AIT Receives Milestone Payment From Commercialization Partner
AIT Therapeutics, Inc. recently announced it has received a milestone payment of $3.15 million from its commercialization partner Circassia Pharmaceuticals for the successful completion of…
